Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 10, 2013

AstraZeneca, Hadasit Launch Drug Discovery Alliance

  • AstraZeneca and Hadasit, the commercial arm and technology transfer company of Israel’s Hadassah University Hospitals, today said they will identify, evaluate, and jointly develop new treatments for several diseases, primarily focused on cancer, respiratory diseases, and diabetes.

    The three dovetail with AstraZeneca’s core therapy areas of oncology; cardiovascular and metabolic disease; and respiratory, inflammation, and autoimmunity diseases. CEO Pascal Soriot halved AstraZeneca’s core therapy areas to three in March, as part of a company restructuring that included 3,900 additional job cuts, and is designed to reverse years of clinical setbacks.

    “AstraZeneca now has a more intense focus on early-stage academic and biotech alliances. We look forward to collaborating with Hadasit on scientific research and pharmaceutical development here in Israel,” David Goren, president of AstraZeneca Israel, said in a statement. “I am convinced this agreement has the potential to strengthen our pipeline of medicines in our core therapy areas.”

    Hadasit and Hadassah scientists will work with teams from AstraZeneca’s innovative medicines and early development organization for an initial period of three years to investigate potential treatments, both biologics and small molecule compounds. The companies said their collaboration is designed to wed Hadasit technologies and research capabilities originating from Hadassah with AstraZeneca’s global research and drug discovery knowhow.

    The value of the collaboration and other financial details were undisclosed.

    Hadasit’s portfolio includes about 170 active patent families tied to medical and commercial breakthroughs, including the cancer treatment liposomal-doxorubicin, developed with Hebrew University.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »